RxDoctor Payments Data

Kelly Bell

Family · Clermont, FLNPI 1124162524

Payments from drug & device makers

$1,226in general payments, 2019–2025

Across 57 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$263
  • Lilly USA, LLC$187
  • Pfizer$142
  • Intuitive Surgical$106
  • Amgen$94
  • Astellas Pharma US Inc$77
  • plus $357 from 13 others

What the payments were for

  • Food & beverage$1,21299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,226 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$68,696
Medicare patients
384
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$30,145
EliquisApixaban24$27,388
MounjaroTirzepatide14$14,738
Breo ElliptaFluticasone/Vilanterol15$7,448
Levothyroxine Sodium135$912
Pantoprazole Sodium55$755
Bupropion XlBupropion Hcl26$723
ValacyclovirValacyclovir Hcl21$705
Atorvastatin Calcium100$697
Rosuvastatin Calcium70$662
Famotidine56$572
Omeprazole40$473
Metoprolol Succinate34$420
Doxycycline Hyclate37$394
Gabapentin38$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$263$30,14523 claims
PfizerEliquis$142$27,38824 claims
Lilly USA, LLCMounjaro$187$14,73814 claims
GSKBreo Ellipta$18$7,44815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →